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Abstract 
 
Background 
Between 1957-1962 thalidomide was used as a non-addictive, non-barbiturate sedative that 
also was successful in relieving the symptoms of morning sickness in early pregnancy. 
Infamously, thousands of babies were subsequently born with severe birth defects. The drug 
is used again, today, to successfully treat leprosy, and tragically, there is a new generation 
of thalidomide damaged children in Brazil. While the outward damage in babies has been 
documented, the effects of the damage upon the survivors as they grow up, the lifestyle 
changes and adaptations required to be made, as well as studies into ageing in survivors, 
has received little attention and remains understudied. 
 
Methods/Results 
A unique multidisciplinary meeting was organised at the University of York bringing together 
thalidomide survivors, clinicians, scientists, historians and social scientists to discuss the 
past, the current and the future implications of thalidomide. 
 
Conclusions 
There is still much to learn from thalidomide, from its complex history and ongoing impact on 
peoples’ lives today, to understanding its mechanism/s to aid future drug safety, to help 
identify new drugs retaining clinical benefit without the risk of causing embryopathy. For 
thalidomide survivors, the original impairments caused by the drug are compounded by the 
consequences of a lifetime of living with a rare disability, and early on-set age related health 
problems. This has profound implications for their quality of life and need for health and 
social care services. It is vital that these issues are addressed in research, and in clinical 
practice if thalidomide survivors are to ‘age well’.  
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Background 
 
Landmark papers in The Lancet by Dr William McBride (McBride, 1961) and Dr Widikund 
Lenz (Lenz, 1962) first drew the medical world’s attention to Thalidomide and the extensive 
damage the drug caused to babies when their mother took it to combat morning sickness in 
early pregnancy. In the immediate aftermath, much was written about the health of babies 
affected, the teratogenic effects of the drug and the scientific and legal implications of the 
‘Thalidomide disaster’ (Smithells and Newman, 1992). Given the drug is now used around 
the world again to successfully treat conditions like leprosy in Brazil, in 2014 a World Health 
Organisation sponsored meeting of experts (World Health Organisation, 2014; www.who-
umc.org/graphics/28280.pdf) reexamined the diagnostic criteria of Thalidomide embryopathy 
and the mechanisms of causation (Vargesson, 2015). This was in response to a new 
generation of thalidomide damaged children being seen in Brazil (Schuler-Facini et al., 2007; 
Vianna et al., 2011; Vargesson, 2013). Yet, the effects of the damage upon the survivors as 
they grow up, has only recently started to be studied. It is really in the past decade, as 
Thalidomide survivors reached their 50’s, there has been renewed interest in their health 
and in particular the effects of ageing with Thalidomide embryopathy. In November 2015, a 
symposium organised by the University of Tokyo focused on clinicians conducting research 
into ageing and early onset age-related effects in people with Thalidomide embryopathy 
(Honoshita, 2015).  
 
However, the issues, both practical and clinical, affecting the day-to-day life of Thalidomide 
survivors have rarely been discussed. In addition an understanding of the long-term 
consequences of thalidomide embryopathy in survivors remains understudied. A recent 
meeting in September 2016 organised by Ms Elizabeth Newbronner and Prof Karl Atkin 
(Department of Health Sciences, University of York) and held at the University of York aimed 
to start a dialogue to begin to address these issues. The Meeting was a truly interdisciplinary 
gathering exploring the broader legacy of Thalidomide. It brought together Thalidomide 
survivors, historians, scientists, clinicians and social scientists to explore what lessons can 
be learnt from the history and use of the drug, its impact and ongoing consequences today; 
and how this knowledge can benefit Thalidomide survivors and others with rare impairments. 
 
Legacy of Thalidomide Meeting 
 
The meeting had three sessions each highlighting different perspectives: historical, 
contemporary and personal. Professor Karl Atkin, Head of the Department of Health 
Sciences at the University of York, opened the day. He remarked on the importance of 
understanding the life course when making sense of long-term conditions and in particular, 
how ageing with a disability creates specific disadvantages which need to be addressed.    
 
The historical perspectives session began with a joint presentation by Dr Ruth Blue, 
(Secretary of the Thalidomide Society and Curator at the Wellcome Library) and Mr Brian 
Payne (Trustee of the Thalidomide Society; http://www.thalidomidesociety.org/). In their talk - 
The thalidomide story: archives and voices - they outlined the history of the Thalidomide 
Society and gave an overview of the practical work they are doing to conserve the history 
and advise researchers and the media. They also highlighted the wealth of Thalidomide 
related reports, papers, photographs and films, held by the Wellcome Library 
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(http://wellcomelibrary.org/). The archive also holds oral history recordings from Thalidomide 
survivors and will soon hold recordings of parents who took the drug. 
 
Dr Julie Parle, (Honorary Associate Professor in History, School of Social Sciences, 
University of KwaZulu-Natal, South Africa) a UK-born Thalidomide Survivor, gave a 
fascinating presentation on the research she and other historians have been doing on the 
‘hidden histories’ of thalidomide’s distribution, impact and use in African countries since the 
1960s (Klausen and Parle, 2015). Her talk showed that Thalidomide has many ‘shadow’ 
histories around the world, even where it has not been proven to have directly affected 
mothers and babies, and how some Thalidomide survivors are themselves now piecing 
these histories together, bit by bit. She argued that more archives need to be opened to 
researchers in pursuit of such histories. 
 
The session concluded with a presentation about Historic photographs for engagement and 
outreach: experiences from the Global Health Histories project by Dr Alex Medcalf (Outreach 
Historian. Centre for Global Health Histories, Department of History, University of York; 
www.york.ac.uk/history/global-health-histories/). This project involves using visual images to 
tell a historical story. He highlighted some of the challenges and complexities they have 
faced in the project, in particular, the ethics of displaying difficult and sensitive material, and 
the importance of using the images to assist the argument or provoke additional questions. 
 
The contemporary perspective session was opened by Dr Neil Vargesson, (Senior Lecturer, 
School of Medicine, Medical Sciences and Nutrition, University of Aberdeen). In his 
presentation -Thalidomide: mechanisms of action and current challenges – he gave an 
overview of current opinion on the drug’s mechanisms, in embryos and in adults (Vargesson, 
2015). The drugs action on blood vessel formation, its ability to induce cell death and interact 
with Cereblon are widely accepted as mechanisms of the drug’s action. Indeed, he 
described how the drug’s actions on blood vessels can result in a range of limb damage 
(Vargesson, 2009; Vargesson, 2015; Vargesson and Hootnick, In Press). He also described 
the advances his team has made in finding a ‘safe’ form of the drug, retaining the clinical 
benefits but without the side-effect of embryonic damage (Beedie et al., 2016; Beedie et al. 
In Press). This is extremely relevant today as sadly new generations of Thalidomide children 
have been born in recent decades in Brazil as the original drug is used to treat a form of 
Leprosy (Schuler-Faccini et al., 2007; Vargesson, 2013; Vianna et al., 2011). 
 
The contemporary health of Thalidomide survivors in Sweden was discussed by Dr Shadi 
Ghassemi Jahani (Consultant Orthopaedic Surgeon, Institute of Clinical Sciences, University 
of Gothenburg, Sweden). Dr Ghassemi Jahani has been researching the orthopaedic 
problems experienced by Thalidomide survivors in Sweden as they age (Ghassami Jahani et 
al., 2014). She set out the findings from her work on osteoarthritis and cervical spine 
deterioration (Ghassami Jahani et al., 2016) and then went on to discuss her recent work on 
Health related quality of life. Her research showed that Thalidomide survivors have 
significantly lower physical health related quality of life compared with the general 
population.  
 
Ms Liz Newbronner (PhD student, Department of Health Sciences, University of York) then 
described her research on the contemporary health of Thalidomide survivors in the UK. 
Despite the drug being distributed in 48 countries, little research into the health of 
Page 4 of 8
John Wiley & Sons, Inc.
Birth Defects Research Part A: Clinical and Molecular Teratology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
5 
 
Thalidomide survivors as they age has been undertaken and the research that has been 
carried out is limited to just seven countries – Australia (Jankelowitz et al., 2013), Canada 
(Vermette and Benegabi, 2013), Germany (Peters et al., 2015), Ireland (O’Carroll et al., 
2011), Japan (Shiga et al., 2015), Sweden (Ghassami Jahani et al., 2016) and the UK 
(Nicotra et al., 2016). Findings from a new national health and wellbeing survey of UK 
Thalidomide survivors (Newbronner and Baxter, 2016), undertaken for the Thalidomide Trust 
(http://www.thalidomidetrust.org/) were discussed. The data shows that the health of 
Thalidomide survivors is declining more rapidly than that of their peers in the general 
population. Whilst this experience is similar in many ways to other people with early onset 
disability, there are some distinctive aspects and pertinent wider lessons for health and care 
services. In particular, the complex nature of Thalidomide damage and the implications of 
comorbidities, both of which call for a strongly collaborative approach between clinicians and 
Thalidomide survivors.  
  
In the final session of the day, three UK Thalidomide survivors gave their personal 
reflections on living and ageing with Thalidomide-induced damage. They highlighted the 
legacy of learning for Thalidomide survivors across the world, other people with rare 
impairments (especially limb difference), and the clinicians and services that support them. 
Geoff Adams-Spink (Deputy Chair, European Dysmelia Reference Information Centre; 
http://www.dysnet.org/), discussed the power of networking between Thalidomide survivors 
and others with limb difference. He mphasised the scope to use networking to address 
contemporary issues such as the need for peer support, the development of ‘workarounds’ 
to support everyday tasks, and improved access to specialist health services. Mr Rowland 
Bareham (Chairman, Thalidomide Trust National Advisory Council) focused on the 
experiences of Thalidomide survivors with hearing damage. Around a third of Thalidomide 
survivors have total or partial hearing loss and this ‘hidden’ group of survivors often 
experience higher levels of poorer mental wellbeing. The day was closed by Dr Craig 
Millward (Member, Thalidomide Trust National Advisory Council) who spoke movingly about 
finding out as a young adult that his disabilities had been caused by Thalidomide, and how 
health problems in middle age had lead him into greater involvement with the Thalidomide 
community.  
 
Conclusions 
The meeting showed that there is still much to learn from Thalidomide, both from its complex 
history and its impact on peoples’ lives today. For Thalidomide survivors, the original 
impairments caused by the drug are being compounded by the consequences of a lifetime of 
living with a rare disability, and early on-set age related health problems. Their health and 
functioning is changing, and this has profound implications for their quality of life and need 
for health and social care services. Clinicians and healthcare services often fail to 
understand the complex nature of Thalidomide damage, nor do they always recognise the 
self-management knowledge Thalidomide survivors have. It is vital that both these issues 
are addressed in research, and in clinical practice if Thalidomide survivors are to ‘age well’. 
Furthermore, the experience of Thalidomide survivors provides lessons for supporting other 
people with rare impairments. In particular, there is a need for a flexible response which 
recognises a person’s active engagement with their condition and is sensitive to the 
consequences of the life course. Finally, the meeting was an important reminder of the 
continued need for research into drug safety and for pharmacovigilance.  
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